Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2256 articles about Gilead Sciences, Inc.
-
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
9/19/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) to treat people with COVID-19 with mild to severe hepatic impairment.
-
Biopharma companies buying stock in one another did not used to be an unusual practice, but experts told BioSpace this is becoming less common due to greater market volatility.
-
The first-in-class antibody-drug conjugate—in combination with Merck’s Keytruda—has shown promising results in a Phase II study of patients with metastatic non-small cell lung cancer.
-
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
9/10/2023
Gilead Sciences, Inc. announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy® in combination with Merck’s anti-PD-1 therapy KEYTRUDA® with or without platinum agents in patients with previously untreated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.
-
Gilead Prices $2 Billion of Senior Unsecured Notes
9/8/2023
Gilead Sciences, Inc. announced the pricing of senior unsecured notes in an aggregate principal amount of $2 billion, in an underwritten, registered public offering, consisting of $1 billion of 5.250% senior notes maturing in 2033 and $1 billion of 5.550% senior notes maturing in 2053.
-
Gilead Sciences: How One School Has Transformed Education for First-Generation Students
9/6/2023
As an elementary school student, Nohely Peraza took a bus from her home in East Palo Alto to a school several miles away in another city.
-
Gilead Sciences: Fifth Anniversary of COMPASS: Helping Address the HIV Epidemic in the U.S. South
8/30/2023
This year marks the fifth anniversary of the Gilead COMPASS Initiative®, a 10-year, more than $100 million commitment to addressing the HIV epidemic in the Southern United States.
-
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
8/24/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment.
-
How Gilead’s Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines
8/23/2023
When Stacey Ma was a little girl, her dream was to work with patients as a doctor.
-
Gilead Sciences to Present at Upcoming September 2023 Investor Conferences
8/23/2023
Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conferences.
-
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
8/21/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia (AML).
-
The biopharma’s acute myeloid leukemia hopeful is on partial clinical hold, affecting two Phase III AML studies, Gilead announced Monday. The CD47 candidate also spent four months on hold in 2022.
-
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
8/18/2023
Gilead Sciences, Inc. (Nasdaq: GILD) and Meharry Medical College today announced the publication of a new supplemental issue of Meharry Medical College’s Journal of Health Care for the Poor and Underserved.
-
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
8/15/2023
Gilead Sciences, Inc. and Tentarix Biotherapeutics announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.
-
The study participant who died was apparently ineligible for the treatment according to the trial protocol, Arcellx announced Monday. The company has since retrained the study’s clinical sites.
-
Thursday, Gilead Sciences reported lower second-quarter profit due to a drop in sales of the company's Veklury antiviral and a $525 million legal settlement, while slightly raising its sales outlook for the year.
-
Gilead Sciences Announces Second Quarter 2023 Financial Results
8/3/2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2023.
-
GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION’S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030
7/28/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of the 2023 Gilead ALL4LIVER Grant, a grant program with the theme of ‘Test. Link. Prioritize’, designed to support innovative projects that drive testing, improve linkage to care and/or elevate viral hepatitis on the public health agenda.
-
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
7/27/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) approved Trodelvy® (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.
-
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
7/24/2023
Gilead Sciences, Inc. announced results from multiple studies reinforcing Biktarvy® as a treatment option for a broad range of people with HIV.